First In-Body CRISPR Gene Therapy Achieves Cure in Phase 3 Trial

Intellia Therapeutics announced groundbreaking Phase 3 clinical trial results for lonvoguran ziclumeran (lonvo-z), the first in vivo CRISPR gene-editing therapy, demonstrating an 87% reduction in hereditary angioedema attacks by curing the disease from within the body.

The top 3

  1. Who Discovered CRISPR-Cas9?: Emmanuelle Charpentier and Jennifer A. Doudna published groundbreaking research on CRISPR-Cas9 as a gene-editing tool in 2012, for which they jointly received the 2020 Nobel Prize in Chemistry.
  2. First Human CRISPR Clinical Trial: In 2016, oncologist Lu You's research team at China's Sichuan University injected CRISPR gene-edited cells into a patient with aggressive lung cancer, marking the first human test of CRISPR.
  3. CRISPR: Key Non-Human Applications: CRISPR technology is used in agriculture to extend tomato shelf life and in medicine to modify mosquitoes to eliminate malaria, with potential roles in tissue engineering and regenerative medicine.

Sources

Open the full topic